Goldman Sachs Group initiated coverage on shares of EXACT Sciences (NASDAQ:EXAS) in a research report report published on Monday morning, MarketBeat reports. The brokerage issued a neutral rating and a $51.00 target price on the medical research company’s stock.

Other analysts have also recently issued research reports about the stock. William Blair reaffirmed a buy rating on shares of EXACT Sciences in a research note on Wednesday, January 10th. Robert W. Baird boosted their target price on shares of EXACT Sciences from $49.00 to $56.00 and gave the stock an outperform rating in a research note on Tuesday, October 31st. Jefferies Group boosted their target price on shares of EXACT Sciences to $60.00 and gave the stock a buy rating in a research note on Tuesday, October 31st. Benchmark reaffirmed a buy rating and set a $60.00 target price (up previously from $50.00) on shares of EXACT Sciences in a research note on Tuesday, October 31st. Finally, Bank of America boosted their target price on shares of EXACT Sciences from $56.00 to $58.00 and gave the stock a buy rating in a research note on Tuesday, October 31st. Eight analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $52.84.

Shares of EXACT Sciences (NASDAQ EXAS) opened at $49.60 on Monday. EXACT Sciences has a one year low of $18.09 and a one year high of $63.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34.

In other news, insider Kevin T. Conroy sold 110,439 shares of EXACT Sciences stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $50.49, for a total transaction of $5,576,065.11. Following the transaction, the insider now owns 940,491 shares in the company, valued at $47,485,390.59. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Kevin T. Conroy sold 137,805 shares of EXACT Sciences stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $59.14, for a total transaction of $8,149,787.70. Following the transaction, the chief executive officer now owns 967,867 shares in the company, valued at approximately $57,239,654.38. The disclosure for this sale can be found here. In the last quarter, insiders have sold 800,499 shares of company stock worth $44,083,803. 4.00% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of EXAS. Krilogy Financial LLC lifted its holdings in shares of EXACT Sciences by 1,460.0% during the second quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after purchasing an additional 3,650 shares during the period. Crow Point Partners LLC acquired a new position in shares of EXACT Sciences during the fourth quarter worth $145,000. Oppenheimer Asset Management Inc. lifted its holdings in shares of EXACT Sciences by 2,925.7% during the third quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock worth $150,000 after purchasing an additional 3,072 shares during the period. SG Americas Securities LLC acquired a new position in shares of EXACT Sciences during the third quarter worth $183,000. Finally, Crescent Grove Advisors LLC acquired a new position in EXACT Sciences in the third quarter valued at $200,000. Institutional investors own 82.02% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/exact-sciences-exas-now-covered-by-goldman-sachs-group/1838707.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.